CJC-1295
CJC-1295 with DAC
A growth hormone releasing hormone (GHRH) analog that stimulates the pituitary to release growth hormone. The 'with DAC' version has a longer half-life due to drug affinity complex.
Typical Cost
$50-120/vial (2mg with DAC)
Status
Research
Peptide Profile
CJC-1295
Mechanism of Action
Binds to GHRH receptors in the pituitary, increasing both the frequency and amplitude of growth hormone pulses. The DAC component extends half-life to approximately 6-8 days. Increases IGF-1 levels.
Common Dosages
subcutaneous
1000-2000mcg
2x weekly · 8-12 weeks
subcutaneous (without DAC)
100-300mcg
1-3x daily · 8-12 weeks
Benefits
Elevated growth hormone
Increased IGF-1
Muscle growth
Fat loss
Improved sleep
Enhanced recovery
Better skin and hair
Side Effects
Water retention
Numbness/tingling
Injection site reactions
Tiredness
Reduced insulin sensitivity
Key Research
CJC-1295 pharmacokinetics
Demonstrated significantly extended half-life and sustained GH elevation with DAC version
CJC-1295 in healthy adults
Showed significant increases in GH and IGF-1 levels with good tolerability
Regulatory Status
Research chemical only. Not FDA-approved. Not available by prescription.
Contraindications
- ⚠Active cancer
- ⚠Diabetic retinopathy
- ⚠Pregnancy/breastfeeding
- ⚠Diabetes
For GLP-1 users optimizing body composition, CJC-1295 combined with SeraVia Muscle+ Protect may support lean mass preservation during weight loss phases.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.